Please login to the form below
Xceleron expands US operations
Xceleron has signed a lease on a multimillion dollar facility in the US to expand its reach in the region
UK-based drug development analytical strategies company, Xceleron, has signed a lease on a multimillion dollar facility in the state of Maryland in the US.
The facility will open in November 2007 housing a new accelerator mass spectrometer (AMS) and employing at least 20 people in scientific, commercial and administrative roles.
The move follows the establishment of Xceleron's North American business in 2005 to meet increased demand in what the company cites as a USD 1bn market worldwide for drug delivery analytics.
CEO of Xceleron, Professor Colin Garner, said: "We will invest up to USD 7.5m on the purchase of a new AMS and associated equipment to carry out analysis on pharmaceutical drug candidates. Our new facility will allow us to substantially increase our development capacity to better serve our customers worldwide."
Dr Pradeep Ganguly, director of the Montgomery County Department of Economic Development, welcomed Xceleron's decision to set up its new accelerator mass Spectrometer (AMS) in the US: "Xceleron is a highly innovative life sciences company, with a technology that will greatly advance drug discovery. We are delighted that this UK-based company has decided to expand in Germantown."
Share
Related Hub content
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- AstraZeneca announces major expansion of Canadian research footprint
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
